# First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

> **NCT03625037** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 666 (actual)

## Conditions studied

- DLBCL
- High-grade B-cell Lymphoma (HGBCL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- FL
- MCL
- Small Lymphocytic Lymphoma (SLL)
- Marginal Zone Lymphoma (MZL)
- Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
- Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)

## Interventions

- **BIOLOGICAL:** Epcoritamab

## Key facts

- **NCT ID:** NCT03625037
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-26
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 666 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625037, "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03625037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*